Aptar Requests U.S. FDA Emergency Use Authorization for N95 Filtering Facepiece Respirator Decontamination with ActivShield™.


Optimizing Patient Adherence and Compliance in Eye Care

Read description

New technologies in ophthalmic drug delivery


Poor patient compliance with drug dosing regimens can be a major impediment to effective treatments. Eye Care diseases such as AMD and Glaucoma are potentially blinding chronic diseases, requiring life-long medical therapy. Failure to adhere to proper treatment may lead to disease progression and visual loss, not to mention economic consequences. Even though the topical application of ophthalmic drugs is quite straightforward, it is common knowledge that poor compliance is widespread. It is often due to a mix of several factors, including drops that sting and the difficulty of applying drops accurately, particularly for older patients. Preservatives play a prominent role in this unfavourable mix, often to the patient’s detriment, so offering preservative-free formulations is of major interest. 

Considering that in terms of both efficacy and safety, topical delivery of drugs, especially for front-of-the-eye indications, is superior to all other administration routes, this presentation will show the available options and discuss future trends, in particular regarding preservatives and debatable additives, but also novel approaches like “Connected Eye Care”.

Specific strategies to address the issues of patient compliance and drug delivery optimization will be discussed. In addition, limitations and regulatory hurdles associated with future methods will be mentioned. Finally, the presentation will examine approaches available now and in the near future that enhance efficacy by improving delivery of ophthalmic formulations.

Compliance and microbiological safety are key for successful preservative-free eye care treatment. Register now to learn more about how to leverage patient adherence with Eye Care medications and how to choose a packaging format that will successfully meets regulatory authorities’ requirements.

Presented by

Matthias Birkhoff V.P. Business Development
Matthias Birkhoff is Vice President Business Development at Aptar Pharma. In this role he is responsible for Aptar Pharma’s Eye Care program and coordinates research and development activities, microbiological assessment and commercial strategies. Matthias started his career in pharmaceutical sales at a major multinational pharmaco before joining Aptar nineteen years ago. Prior to his involvement in Business Development and Marketing, Matthias was in charge of sales in the AsiaPacific region. He studied medicine at the University of Dusseldorf, Germany and holds a nursing degree. Matthias has recently spoken at international events, such as NDD (Nasal Drug Delivery), London/UK, PMP (Pharmaceutical Plastics), Copenhagen/Denmark, Interphex, Tokyo/Japan, CPHI, Pharmapack, AAPS, or the IPA conference in Mumbai/India.
Dr. Degenhard Marx Director Scientific Affairs
Dr. Degenhard Marx is Director Scientific Affairs within the Aptar Pharma Consumer Health Care Division. Following the study of veterinary medicine and the successful completion of his thesis at the University of Leipzig in 1992, he joined the pharmaceutical industry. There he collected ample experiences in the drug development of anti-inflammatory and cardio-vascular drugs. In 2008, he became business development manager within Aptar Pharma.
Please register to view the webinar :Already registered ?
Mandatory fields

*The information marked with (*) is essential to process your request. Failure to provide such information may prevent us from fulfilling your request. Your personal data will be used only for Aptar to process an information request and/or job application and will be made accessible to Aptar and to any third party for exclusively technical and logistical reasons, notably to our services located outside the European Union, being specified that, in the event that the recipient country does not ensure a level of data protection equivalent to that of the European Union, Aptar undertakes to take all relevant guarantees, either on the basis of an adequacy decision or, in the absence of such a decision, on the basis of appropriate safeguards, a copy of which may be requested from the contact email below. Your personal data will only be kept for a period that does not exceed the applicable statutory limitation periods. Any contact data will be made accessible to Aptar and to third parties that provide technical and logistical support to Aptar for the purpose of your contact request.

If any after communication upon receipt of a valid identity document, you have the right to access, modify, rectify, limit, delete and ask, if any, the portability of your personal data as well as a right of opposition, if necessary subject to legitimate and imperative reasons, to the processing of such data. You may also define guidelines for the use of your personal data in the event of death.

If you wish to exercise this option or if you have any questions regarding our General Terms and Conditions of Use, Privacy and Cookies Policy, please contact Aptar at: informationgovernance@aptar.com

You also have the right to lodge a complaint at the relevant data protection authority in your own jurisdiction.

November 21, 2017 3PM London/10AM New York 60 min
Watch now
Presented by
Matthias Birkhoff V.P. Business Development
Dr. Degenhard Marx Director Scientific Affairs
Read more
Key Learning Objectives
  • Key Learning Objectives
  • Importance of Microbiological Safety for preservative-free applications
  • Reliable drug delivery systems that meet Regulatory requirements
  • Successful use of Connected Health within the field of drug delivery systems for Eye Care applications
  • How to select a drug delivery system that ensures intuitive handling
Do you have questions about this webinar ?
Contact us